乳腺癌患者基于内分泌治疗和年龄的骨折风险差异:一项全国性队列研究
该回顾性队列研究利用韩国中央癌症登记和国民健康保险服务数据,分析2008至2016年间63,021例新诊断乳腺癌患者,按术后内分泌治疗比较他莫昔芬与芳香化酶抑制剂(AI)使用者和非使用者在不同年龄段的骨折发生率。结果显示,50岁以上他莫昔芬组任何骨折风险降低(HR=0.75,95%CI 0.62-0.89,p<0.001),50岁以下AI组骨折风险显著增加(HR=1.54,95%CI 1.07-2.93,p=0.019);50岁以上AI组与非使用者相比骨折风险未增加。
要点
- 50岁以上乳腺癌患者他莫昔芬组任何骨折风险降低(HR=0.75,95%CI 0.62-0.89,p<0.001),50岁以下无此保护。
- 50岁以下AI组骨折风险显著增加(HR=1.54,95%CI 1.07-2.93,p=0.019),50岁以上AI组未增加。
- 骨质疏松性骨折总发生率为7.4/1000人年,50岁以下3.5/1000人年,50岁以上12.6/1000人年。
核心结论
- 在50岁以上乳腺癌患者中,AI使用与非使用者相比骨折风险未增加。
- 他莫昔芬使用与骨折风险降低相关,但50岁以下患者无此关联。
- 考虑到韩国乳腺癌诊断年龄相对年轻,需长期随访研究。
研究设计与样本
- 回顾性队列研究,使用韩国中央癌症登记和韩国国民健康保险服务数据。
- 分析2008至2016年间63,021例新诊断乳腺癌患者。
- 采用多变量Cox比例风险模型分析术后内分泌治疗与骨折风险的关系。
主要发现
- 69.1%的患者接受了内分泌治疗。
- 骨质疏松性骨折发生率:总体7.4/1000人年,50岁以下3.5/1000人年,50岁以上12.6/1000人年。
- 调整混杂因素后,50岁以上他莫昔芬组任何骨折风险降低(HR=0.75,95%CI 0.62-0.89,p<0.001),50岁以下他莫昔芬组无此保护。
- 50岁以下AI组骨折风险显著增加(HR=1.54,95%CI 1.07-2.93,p=0.019),50岁以上AI组未增加。
局限性
- 原文报告需长期随访研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Concerns about the risk of osteoporosis and osteoporotic fractures following endocrine therapy have increased with increase in breast cancer survivors. This study aimed to evaluate the incidence of fractures by site between tamoxifen and aromatase inhibitor (AI) users and non-users at premenopausal and postmenopausal ages. METHODS: This retrospective cohort study used data from the Korea Central Cancer Registry and the Korean National Health Insurance Service. We analyzed 63,021 newly diagnosed breast cancer patients between 2008 and 2016. The risk of fractures was analyzed according to post-surgical endocrine therapy using the multivariable Cox proportional hazard model. RESULTS: Herein, 69.1% of the patients received endocrine therapy. The incidence rates of osteoporotic fractures per 1,000 person-years were 7.4 overall, 3.5 in those under 50, and 12.6 in those over 50. After adjusting for confounders, the tamoxifen group showed protection against any fractures in patients over 50 (HR = 0.75, 95% CI 0.62-0.89, p < 0.001) but not in those under 50. The AI group was associated with a significant increase in fractures in those under 50 (HR = 1.54, 95% CI 1.07-2.93, p = 0.019) but not in those over 50. CONCLUSION: Among breast cancer patients aged over 50 years, AI use was not associated with increased risk of compared to non-users. Tamoxifen use was linked to reduced risk of fracture, but not in patients under 50. Considering the relatively young age of breast cancer diagnosis in Korea, long-term follow-up studies are warranted. After adjusting for confounders including age, among breast cancer patients aged over 50 years, AI use was not associated with increased risk of fracture compared to non-users. Tamoxifen use was linked to reduced risk of fracture, but not in patients under 50.
引用
- Kwak MK, Lee S, Lee JY, et al. Differential fracture risk in breast cancer patients based on endocrine therapy and age: a nationwide cohort study. Osteoporos Int. 2025. PMID: 41091161. doi:10.1007/s00198-025-07639-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。